ArticleFrontiers in oncology2020

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.

Emanuele Perrone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.